Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 23475547)

1.

Preliminary experience with use of recombinant activated factor VII to control postpartum hemorrhage in acute fatty liver of pregnancy and other pregnancy-related liver disorders.

Goel A, Nair SC, Viswabandya A, Masilamani VP, Rao SV, George A, Regi A, Jose R, Zachariah U, Subramani K, Eapen CE, Chandy G.

Indian J Gastroenterol. 2013 Jul;32(4):268-71. doi: 10.1007/s12664-013-0315-4. Epub 2013 Mar 10.

PMID:
23475547
2.

Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.

Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, Ogle R, Cameron PA; Australian and New Zealand Haemostasis Registry.

Anesth Analg. 2009 Dec;109(6):1908-15. doi: 10.1213/ANE.0b013e3181c039e6.

PMID:
19923520
3.

Acute coagulopathy after reperfusion of the liver graft in children correction with recombinant activated factor VII.

Markiewicz M, Kalicinski P, Kaminski A, Laniewski P, Ismail H, Drewniak T, Szymczak M, Nachulewicz P.

Transplant Proc. 2003 Sep;35(6):2318-9.

PMID:
14529927
4.

Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.

Mitsiakos G, Papaioannou G, Giougi E, Karagianni P, Garipidou V, Nikolaidis N.

J Pediatr Hematol Oncol. 2007 Mar;29(3):145-50.

PMID:
17356391
5.

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Pediatr Hematol Oncol. 2008 Jun;25(4):301-11. doi: 10.1080/08880010802016904.

PMID:
18484474
6.

[Our experince with the use of recombinant activated factor VII in postpartum haemorrhage].

Mostić T, Sparić R, Argirović R, Ljubić A, Bozanović T, Arsenijević L, Tomanović-Koković J, Stefanović A.

Srp Arh Celok Lek. 2008 Sep;136 Suppl 3:204-9. Serbian.

PMID:
19562869
7.

[Effect of recombinant activated factor VII (RFVIIA; NovoSeven) in a patient in haemorrhagic shock after obstetrical hysterectomy].

Sobieszczyk S, Breborowicz GH, Markwitz W, Mallinger S, Adamski D, Kruszyński Z.

Ginekol Pol. 2002 Mar;73(3):230-3. Polish.

PMID:
12092258
8.

Massive postpartum hemorrhage: recombinant factor VIIa use is safe but not effective.

Kalina M, Tinkoff G, Fulda G.

Del Med J. 2011 Apr;83(4):109-13.

PMID:
21675158
9.

Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.

Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O.

Vox Sang. 2004 Jul;87(1):34-40. Review.

PMID:
15260820
10.

Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.

Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG.

Liver Transpl. 2003 Feb;9(2):138-43.

11.

Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.

Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS.

Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7. doi: 10.1016/j.athoracsur.2008.01.089.

PMID:
18442563
12.
13.

Use of recombinant activated factor VII for massive postpartum hemorrhage.

Hossain N, Shansi T, Haider S, Soomro N, Khan NH, Memon GU, Farzana T, Ansari S, Triche EW, Kuczynski E, Lockwood CJ, Paidas MJ.

Acta Obstet Gynecol Scand. 2007 Oct;86(10):1200-6.

PMID:
17851797
14.

A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.

Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G.

Semin Thromb Hemost. 2008 Feb;34(1):104-12. doi: 10.1055/s-2008-1066022. Review.

PMID:
18393147
15.

Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients.

Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT.

Neurosurgery. 2003 Jul;53(1):34-8; discussion 38-9.

PMID:
12823871
16.

Recombinant activated factor VII (rFVIIa/NovoSeven®) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan.

Kobayashi T, Nakabayashi M, Yoshioka A, Maeda M, Ikenoue T.

Int J Hematol. 2012 Jan;95(1):57-63. doi: 10.1007/s12185-011-0974-9. Epub 2011 Dec 9.

PMID:
22160834
17.

[Off-label use of recombinant factor VII (rFVIIa) in teaching hospitals in Paris in 2010].

Bardon J, Fink J, de Montblanc J, Bergmann JF, Sarrut B, Benhamou D.

Ann Fr Anesth Reanim. 2013 Oct;32(10):659-64. doi: 10.1016/j.annfar.2013.05.007. Epub 2013 Aug 13. French.

PMID:
23953834
18.

Preemptive administration of recombinant factor VII (rVIIa) in patients transplanted due to fulminant Wilson's disease.

Czuprynska MM, Wawrzynowicz-Syczewska M, Jureczko L, Andrzejewska J, Jarosz K, Trzebicki J, Pacholczyk M, Chmura A, Wojcicki M.

Ann Transplant. 2010 Jul-Sep;15(3):7-10.

PMID:
20877260
19.

Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004.

Alfirevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H, Mercier F, Ahonen J, Bremme K, Bødker B, Magnúsdóttir EM, Salvesen K, Prendiville W, Truesdale A, Clemens F, Piercy D, Gyte G.

Obstet Gynecol. 2007 Dec;110(6):1270-8.

PMID:
18055720
20.

Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa).

Segal S, Shemesh IY, Blumenthal R, Yoffe B, Laufer N, Ezra Y, Levy I, Mazor M, Martinowitz U.

Arch Gynecol Obstet. 2003 Oct;268(4):266-7. Epub 2002 Nov 7.

PMID:
14504866
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk